GleamWall
中文EN

IMCR Immunocore Holdings plc

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1671927 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.1%
TTM net income YoY-9.9%
TTM EPS YoY-10.3%
Revenue 3-yr CAGR25.9%
Net income 3-yr CAGR—

Margins

Gross margin98.9%
Operating margin-6.8%
Net margin-7.5%
FCF margin-4.2%
EBITDA margin-5.9%

Returns

ROE-7.9%
ROA-2.9%
ROIC (approx.)—
Asset turnover0.38x

Leverage & solvency

Liabilities / assets62.8%
Debt / equity0.00x
Current ratio4.62x
Interest coverage-2.37x

Cash quality & payout

Operating cash flow / net income0.32x
Accruals ratio-1.9%
Payout ratio—
Capex / revenue1.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$102.22M$115.93M$106.68M$104.48M$103.69M$97.96M$93.88M$84.05M
Cost of revenue$676,000$1.09M$434,000$2.70M$513,000$1.04M$831,000$330,000
Gross profit$101.55M$114.84M$106.24M$101.78M$103.18M$96.92M$93.05M$83.72M
R&D expense$74.70M$73.94M$61.11M$78.82M$70.57M$69.01M$56.47M$60.85M
SG&A expense$40.45M$43.89M$37.85M$42.65M$39.78M$42.79M$40.20M$42.32M
Operating income-$13.61M-$3.00M$7.28M-$19.69M-$7.17M-$14.88M-$3.62M-$19.45M
Interest expense$3.06M$3.06M$3.05M$3.05M$3.04M$3.04M$3.02M$7.04M
Pretax income-$14.07M-$514,000$13.27M-$15.79M$304,000-$9.69M$6.08M-$24.82M
Income tax$153,000$294,000$301,000$14.27M$481,000$606,000$1.06M-$1.05M
Net income-$14.22M-$808,000$12.97M-$30.06M-$177,000-$10.30M$5.02M-$23.77M
EBITDA-$12.50M-$1.97M$8.23M-$19.02M-$6.37M-$14.10M-$2.76M-$18.29M
EPS (basic)-0.28-0.020.26—0.00-0.200.10—
EPS (diluted)-0.28-0.020.25—0.00-0.200.10—
Weighted avg. shares (diluted)51.56M50.97M52.93M—50.40M50.29M51.95M—
Balance sheet
Cash & equivalents$512.25M$484.92M$452.68M$467.71M$498.41M$487.93M$476.85M$455.73M
Short-term investments$389.05M$395.29M$392.22M$396.44M$393.94M$394.88M$360.19M$364.64M
Receivables———————$63.01M
Inventory$7.47M$7.79M$8.25M$6.74M$5.66M$5.46M$6.80M$5.45M
Current assets$1.06B$1.05B$1.00B$996.74M$1.02B$1.00B$948.62M$929.86M
PP&E, net$14.05M$12.86M$12.13M$11.46M$9.43M$9.55M$9.77M$10.09M
Total assets$1.13B$1.12B$1.07B$1.07B$1.10B$1.08B$1.03B$1.01B
Current liabilities$229.62M$235.20M$240.11M$246.70M$170.35M$170.08M$149.16M$212.18M
Total liabilities$709.53M$699.62M$678.42M$686.24M$705.94M$693.91M$649.53M$648.79M
Shareholders' equity$419.71M$419.80M$393.67M$381.03M$396.56M$388.48M$378.48M$360.72M
Shares outstanding51.64M51.48M50.83M50.69M50.47M50.37M50.18M50.06M
Cash flow statement
Operating cash flow$20.09M$15.93M-$13.78M-$32.66M-$4.46M$25.96M$435,000-$13.95M
Capital expenditure$2.35M$786,000$1.78M$2.88M$748,000$414,000$298,000$3.58M
Free cash flow$17.74M$15.14M-$15.56M-$35.53M-$5.20M$25.55M$137,000-$17.54M
Investing cash flow$4.65M-$786,000$4.22M-$880,000$5.25M-$30.41M$9.70M-$3.54M
Financing cash flow$3.75M$16.48M$656,000$4.28M$1.87M$3.67M$2.55M-$51.51M
Depreciation & amortization$1.11M$1.03M$948,000$668,000$798,000$780,000$854,000$1.16M
Stock-based compensation$9.73M$9.40M$6.30M$8.34M$9.84M$10.03M$9.49M$8.67M

Free plan shows the latest 8 periods; Pro shows all 20 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.